1 Dept of Computing and Data Science Institute, Imperial College London, London, UK.
2 National Heart and Lung Institute, Imperial College London, and Biomedical Research Unit, Royal Brompton and Harefield NHS Trust, London, UK.
3 Janssen Research and Development, High Wycombe, UK.
4 Centre for Respiratory Medicine and Allergy, Institute of Inflammation and Repair, University of Manchester and University Hospital of South Manchester, Manchester, UK.
5 Respiratory Research Unit, University of Nottingham, Nottingham, UK.
6 NIHR Southampton Respiratory Biomedical Research Unit, Clinical and Experimental Sciences and Human Development and Health, Southampton, UK.
7 Respiratory Therapeutic Unit, GSK, Stockley Park, UK.
8 AstraZeneca R&D, Molndal, Sweden.
9 Areteva R&D, Nottingham, UK.
10 European Institute for Systems Biology and Medicine, CNRS-ENS-UCBL-INSERM, Lyon, France.
11 Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
12 Respiratory Global Medicines Development, AstraZeneca, Gothenburg, Sweden.
At 1 year, 45% of severe asthma change molecular phenotype as determined by sputum transcriptomic analysis. Together with concomitant shift in sputum granulocytic markers, this may indicate variability of driving mechanisms in this unstable group.https://bit.ly/35aj489